PharmaNet Development Group, Inc. to Announce Fourth Quarter and Full Year 2006 Financial Results on March 1, 2007
11 January 2007 - 12:05PM
Business Wire
PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading
provider of drug development services, today announced that it will
release its fourth quarter and full year 2006 financial results on
Thursday, March 1, 2007 before the market opens. Following the
pre-market release, the Company plans to host a conference call and
webcast to review these results at 8:30 a.m. Eastern Time. Fourth
Quarter and Full Year 2006 Earnings Conference Call: When:
Thursday, March 1, 2007 at 8:30 a.m. Eastern Time Dial-in: (866)
713-8563 for U.S. (617) 597-5311 for International Pass code:
65023741 Dial-in Replay: (888) 286-8010 for U.S. (617) 801-6888 for
International Pass code: 53682689 Available approximately two hours
after the call through Thursday, March 8, 2007 Webcast: Please
visit www.pharmanet.com and select the investor tab to access the
webcast. The archived webcast will be available for approximately
thirty (30) days following the conference call. About PharmaNet
Development Group, Inc. Certain statements made in this press
release are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 (the "Act").
Additionally words such as "seek," "intend," "believe," "plan,"
"estimate," "expect," "anticipate" and other similar expressions
are forward-looking statements within the meaning of the Act. Some
or all of the results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include, but are not limited to, industry trends
and information; whether adverse publicity relating to the
Company�s discontinued Florida operations causes clients to select
competitors, not only for early stage branded clinical trials but
also for other aspects of the Company�s business; its ability to
comply with the timeline agreed upon in the settlement reached with
the Miami-Dade County Unsafe Structures Board and any related fines
or expenses if we are unsuccessful complying with such timeline;
the associated costs and expenses with discontinuing the Company's
operations in Florida, including the potential costs of the
demolition of the Miami facility; the Company's ability to
determine its impairment charges and costs of discontinued
operations; whether the Company will achieve its estimated value
for its Miami property; developments with respect to the SEC's
inquiry and securities class action lawsuits and derivative
lawsuits; the Company�s ability to successfully achieve and manage
the technical requirements of specialized clinical trial services,
while complying with applicable rules and regulations; regulatory
changes; changes affecting the clinical research industry; a
reduction of outsourcing by pharmaceutical and biotechnology
companies; the Company�s ability to compete internationally in
attracting clients in order to develop additional business; the
Company�s evaluation of its backlog and the potential cancellation
of contracts; its ability to retain and recruit new employees; its
clients' ability to provide the drugs and medical devices used in
its clinical trials; the Company�s future stock price; its
assessment of its effective tax rate; the Company�s financial
guidance; our future effective tax rate; our anticipated 2006
capital expenditures; our 2006 costs of compliance of Section 404
of the Sarbanes-Oxley Act; our ability to remediate our material
weaknesses; the impact of foreign currency transaction costs and
the effectiveness of any hedging strategies that we implement; and
the national and international economic climate as it affects drug
development operations. Further information can be found in the
Company�s risk factors contained in its Annual Report on Form 10-K
for the year ended December 31, 2005, which were originally filed
as SFBC International (NASDAQ: SFCC) and its most recent Quarterly
Report on Form 10-Q. The Company does not undertake to update the
disclosures made herein, and you are urged to read our filings with
the Securities and Exchange Commission.
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2024 to Jul 2024
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Pharmanet Development Grp (MM) (NASDAQ): 0 recent articles
More PharmaNet Development Group, Inc. News Articles